New heart zapping tech tested for stubborn AFib

NCT ID NCT05408754

Completed Disease control Sponsor: Adagio Medical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two new devices that use energy pulses to treat persistent atrial fibrillation (a type of irregular heartbeat). 89 adults who had not responded to medication received a heart ablation procedure. The goal was to see if the devices are safe and can stop abnormal heart rhythms for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pulsed field ablation and pulsed field cryoablation systems (devices that use energy to destroy heart tissue causing abnormal rhythms)
What this could lead to: If successful, this could provide a safer, more effective way to treat persistent atrial fibrillation, potentially reducing the need for long-term medication.
What could go wrong: This is an early, first-in-human study with only 89 participants, so results may not apply to everyone. There are risks of procedure-related complications like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Blackrock Health

Dublin, A94 E4X7, Ireland
McGill University Health Centre (MUHC), Montreal General Hospital (MGH)

Montreal, Quebec, H3G 1A4, Canada
Nemocnice Na Homolce

Prague, 150 30, Czechia
Onze-Lieve-Vrouwziekenhuis (OLV)

Aalst, B-9300, Belgium
St Antonius Ziekenhuis

Nieuwegein, 3435, Netherlands
St George'S University Hospital

London, SW17 0QT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.